Post-initiation chlorophyllin exposure does not modulate aflatoxin-induced foci in the liver and colon of rats

Gayle A Orner*1, Bill D Roebuck2, Roderick H Dashwood1,3 and George S Bailey1,3

Address: 1Linus Pauling Institute, Oregon State University, Corvallis, OR, USA, 2Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, NH, USA and 3Environmental and Molecular Toxicology Department, Oregon State University, Corvallis, OR, USA

Email: Gayle A Orner* - gayle.orner@orst.edu; Bill D Roebuck - bill.roebuck@dartmouth.edu; Roderick H Dashwood - rod.dashwood@oregonstate.edu; George S Bailey - george.bailey@oregonstate.edu

* Corresponding author

Abstract

Chlorophyllin (CHL) is a promising chemopreventive agent believed to block cancer primarily by inhibiting carcinogen uptake through the formation of molecular complexes with the carcinogens. However, recent studies suggest that CHL may have additional biological effects particularly when given after the period of carcinogen treatment. This study examines the post-initiation effects of CHL towards aflatoxin B1 (AFB1)-induced preneoplastic foci of the liver and colon. The single concentration of CHL tested in this study (0.1% in the drinking water) had no significant effects on AFB1-induced foci of the liver and colon of rats.

Background

During the past decade chlorophyllin (CHL) has progressed from initial in vitro anti-mutagenicity experiments to in vivo studies of anti-tumor mechanisms in trout, mice, and rats [reviewed by [1]], and into successful chemoprevention trials in humans exposed to dietary aflatoxin B1 (AFB1) [2]. An important mechanism for the protective effects of CHL as a blocking agent appears to be the ability of this planar compound to complex with carcinogens, thus preventing carcinogen-DNA adduction. However, several recent studies focusing on post-initiation effects of CHL suggest that CHL may have additional effects independent of molecular complex formation. In one report, CHL caused a concentration dependent suppression of liver tumor formation in rats treated with the heterocyclic amine, 2-amino-3-methylimidazo [4,5-f]quinoline (IQ) [3]. In that study, CHL treatment was started 1 week after the last dose of carcinogen, suggesting that CHL might be effective as a suppressing agent in the liver. Although CHL suppressed IQ-induced liver carcinogenesis in the rat, deleterious effects have been reported in the colon, including tumor promotion in some studies [3,4]. These additional biological properties of CHL could possibly be mediated through effects on apoptosis [5] or drug metabolism [6-8].

In the present study, we examined the post-initiation effects of CHL towards AFB1-induced putative preneoplastic foci of the liver and colon.

Methods

Animals

Male F344 rats, 3 weeks of age were purchased from the National Cancer Institute (Frederick, MD) and housed two per cage in shoebox cages at 22 °C on a 12 hr light/dark cycle. All rats were fed AIN-93G diet (Dyets Inc., Bethle-
ham, PA) ad libitum. Prior to and during the period of carcinogen administration, the diet was free of ethoxyquin since this antioxidant prevents the formation of putative preneoplastic foci in rat livers [9]. Cardboard tubes were provided for environmental enrichment. Rats were weighed weekly throughout the experiment.

**Chemicals**

CHL was a gift from Dr. T.W. Kensler and was lot-matched to the CHL preparation used in the human clinical trial [2]. AFB1 was obtained from Aldrich (Milwaukee, WI). All other chemicals were obtained from Sigma-Aldrich (St. Louis, MO).

**Experimental design**

Following a two-week acclimation to antioxidant free AIN-93G diet, rats were randomly assigned to one of four treatment groups as shown in figure 1. Rats were given trioctanoin (groups 1 and 2) or 250 µg/kg AFB1 in trioctanoin (groups 3 and 4) five times per week for two weeks by oral gavage. Beginning one week after the last AFB1 gavage, and continuing for 12 weeks, groups 2 and 4 were given 0.1% CHL in their drinking water. Fresh CHL solutions were prepared and administered every other day. After 12 weeks of CHL treatment rats were euthanized with carbon dioxide and livers and colons removed.

**Quantification of GST-P positive hepatic foci**

Livers were sliced into multiple 3 mm sections, fixed in acetone, and processed for histology using the AmesX fixation and processing procedure [10]. Slides were stained for expression of GST-P and examined by light microscopy as previously described [11]. The volume percent of liver occupied by GST-P positive foci is considered the least biased and most analogous to tumor burden [12]; therefore, this was the primary endpoint evaluated.

**Quantification of colonic ACF**

Colons were removed, washed with chilled phosphate buffered saline, fixed mucosa side up in 10% phosphate buffered formalin, stained with 0.2% methylene blue, and ACF scored as previously described [13]. All samples were coded so that the individual analyzing them was blinded to the treatment group and animal numbers.

**Statistical analysis**

Results are expressed as means ± S.D. within a treatment group. Data were evaluated by analysis of variance (ANOVA) with post-hoc Tukey's and Bonferroni multiple comparison tests. Analyses were performed using the SAS or StatView statistical packages (SAS Institute, Cary, NC).

**Results**

Rats treated with AFB1 had significantly lower growth rates than vehicle-treated animals; however, there were no significant differences in growth rates (Fig. 2) or food or liquid consumption (not shown) between the water and CHL-treated rats.

GSTM-P positive foci were seldom observed in vehicle-treated rats (0.07 foci/cm² liver examined); but were common in AFB1-treated rats (11 foci/cm²) (Fig. 3A). Twelve weeks of post-initiation treatment with 0.1% CHL had no significant effects on AFB1-induced GST-P positive focal density (Fig. 3A) or volume percent of liver occupied with GST-P positive foci (Fig. 3B).

The AFB1 treatment regime utilized in this study resulted in aberrant crypt foci (ACF) in colons of 80% of AFB1-
treated rats (Examples are shown in Figure 4). These putative preneoplastic foci were not found in the colons of vehicle-treated animals. Post-initiation treatment with 0.1% CHL had no significant effect on the incidence, multiplicity, or size of ACF (Figure 4A–C).

**Discussion/conclusion**

CHL is a promising chemopreventive agent that is believed to block the bioavailability of certain carcinogens by forming complexes with the carcinogen. CHL is a highly effective blocking agent in animal models and was recently shown to be effective at reducing urinary aflatoxin-DNA adduct biomarkers in humans exposed to high levels of dietary aflatoxins [2]. In addition to the well-established carcinogen blocking mechanism of CHL, some studies suggest that CHL may have additional biological properties. The dose-dependent suppression of IQ-induced liver tumor formation by CHL [3] raises the exciting possibility that the benefit of CHL towards hepatocarcinogenesis could be even greater than predicted by reductions in DNA adduct formation. However, the mixed results of CHL towards colon carcinogenesis [3,4,14] suggest that under certain circumstances CHL may have detrimental effects.

Although AFB1 is primarily considered a liver carcinogen, lifetime exposure also produces colon tumors in rats, particularly in vitamin A deficient animals [15-17]. Based on two case reports of aggressive colon cancer in humans occupationally exposed to aflatoxins [18] and the presence of AFB1 DNA-adducts in colorectal cancer tissue from patients in the United Kingdom [19], the colon may also be a target organ of AFB1 carcinogenesis, particularly in parts of the world where hepatitis B infection is uncommon. Although the primary purpose of this study was to examine the post-initiation effects of CHL on preneoplastic foci of the liver, this experiment also provided an opportunity to determine if the AFB1 exposure protocol routinely used to produce altered hepatic foci in rats also results in preneoplastic lesions of the colon. Indeed, this AFB1 exposure produces a high incidence and multiplicity of ACF and provides a unique opportunity to simultaneously examine the effects of chemopreventive agents on preneoplastic foci of both the liver and colon.

Hepatic GST-P positive foci and colonic ACF are well-established markers for estimating the effect of chemopreventive agents on tumor outcome. GST-P positive foci accurately predicted the protective effects of oltipraz towards AFB1-induced hepatocarcinogenesis [20] and the potency of over 60 chemopreventive agents at inhibiting ACF correlates extremely well with their effects on tumor formation [21].

However, the process of tumor development is complex and our understanding of which preneoplastic markers will progress to tumors is incomplete. Recently the role of ACF as precancerous lesions has been challenged by studies suggesting that mucin depleted foci [22,23], beta-catenin accumulated crypts [24,25], or other atypical foci [26] may be of greater value at predicting tumor formation than the typical ACF first described by Bird in 1987 [27]. While the strong correlation between ACF and colorectal cancer in laboratory animals [21] and their presence in humans at risk for colorectal cancer [28-30] continue to support the utility of these foci for predicting tumor outcome, we recognize that no preneoplastic markers can fully replace tumors as the ultimate endpoint. Therefore, additional studies examining the post-initiation effects of CHL towards AFB1-initiated liver and colon cancer may be appropriate as the use of this chemopreventive agent becomes more widespread. However, the current study suggests that post-initiation treatment with 0.1% CHL is unlikely to modulate liver or colon tumor formation based on the lack of effects towards the formation of AFB1-induced hepatic GST-P positive foci and colonic ACF.

**Figure 3**

Effects of CHL and AFB1 on liver GST-P positive foci. Data are mean (± SE) for each treatment group. (A) No. Foci per cm². (B) Volume percent of liver occupied by foci.
Effects of CHL and AFB$_1$ on colonic ACF. Data are mean (± SE) for each treatment group. (A) Incidence (% of animals with ACF). (B) Number of ACF per colon. (C) Size (# crypts) of ACF. Insert photos show examples of foci containing (A) two, (B) four, and (C) seven aberrant crypts.

**Figure 4**
A major limitation of this study is that only a single concentration of CHL (0.1%) was tested. This concentration was selected because 0.1% CHL is the concentration that is most effective at inhibiting IQ induced liver tumors [3]. However, promotion of DMH-induced colon tumors occurs at much lower CHL concentrations (0.001%) [3]. Additional studies examining a range of CHL concentrations are necessary before concluding that CHL does not enhance AFB1-induced colon carcinogenesis. However, this study demonstrates that the protocol used to examine effects of chemopreventive agents towards AFB1-induced altered hepatic foci can include preneoplastic foci of the colon as an additional endpoint.

Authors' contributions

GAO assisted in the design of the project, performed the animal study, performed the ACF scoring, and drafted the manuscript. BDR assisted in the design of the project, performed the ACF scoring, and drafted the manuscript. RHD assisted in the design of the study, supervised GAO, and helped to draft the manuscript. GSB assisted in the design of the project, and helped to draft the manuscript. GB assisted in the design of the study, supervized GAO, and helped to draft the manuscript.

Acknowledgements

We are grateful to P.A. Egner and Dr. T.W. Kensler for providing CHL. We thank D.L. MacMillan, G.D. Diaz, K. Fischer, M. Pratt, P. Loveland, M. Louderback, Q. Li, and M. Dashwood for assistance in scoring foci, sampling, animal care, or reagent preparation. Funding was provided by the Linus Pauling Institute, Oregon State University and by CA90890, CA65525, CA100608, ES00210, and ES03850.

References

1. Dashwood RH: Chlorophyll as anticarcinogens. International Journal of Oncology 1997, 10:721-727.
2. Egner PA, Wang JB, Zhu YR, Zhang BC, Wu Y, Zhang QN, Qian GS, Kuang SY, Gange SJ, Jacobson LP, Helzlsouer KJ, Bailey GS, Groopman JD, Kensler TW: Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer. Proc Natl Acad Sci U S A 2001, 98(25):14601-14606.
3. Xu M, Orner GA, Bailey GS, Stoner GD, Horio DT, Dashwood RH: Post-initiation effects of chlorophyllin and indole-3-carbolin in rats given 1,2-dimethylhydrazine or 2-amino-3-methylimidazo[4,5-f]quinoline-induced colonocytic aberrant crypt foci. Carcinogenesis 2001, 22(2):309-314.
4. Nelson RL: Chlorophyllin, an antimutagen, acts as a tumor promoter in the rat-dimethylhydrazine colon carcinogenesis model. Anticancer Res 1992, 12(3):737-739.
5. Diaz GD, Li Q, Dashwood RH: Caspase-8 and apoptosis-inducing factor mediate a cytochrome c-independent pathway of apoptosis in human colon cancer cells induced by the dietary phytocarcinogen chlorophyllin. Cancer Res 2003, 63(4):1254-1261.
6. Yun CH, Jeong HG, Jhoun JW, Guengerich FP: Non-specific inhibition of cytochrome P450 activities by chlorophyllin in human and rat liver microsomes. Carcinogenesis 1995, 16(6):1437-1440.
7. Dingley KH, Ubick EA, Chiarella-Zucca ML, Nowell S, Abel S, Ebeler SE, Mitchell AE, Burns SA, Steinberg MP, Clifford AJ: Effect of dietary constituents with chemopreventive potential on adduct formation: a study of the heterocyclic amines PhIP and IQ and phase II hepatic enzymes. Nutr Cancer 2003, 46(2):212-221.
8. Fahey JW, Stephenson KK, Dinkova-Kostova AT, Egner PA, Kensler TW, Talay P: Chlorophyllin, chlorophyll and related tetrapyrroles are significant inducers of mammalian phase II cytoprotective genes. Carcinogenesis 2005, 26(7):1247-1255.
9. Kensler TW, Egner PA, Davidson NE, Roebuck BD, Pilkul A, Groopman JD: Modulation of aflatoxin metabolism, aflatoxin-N7-guanine formation, and hepatic tumorogenesis in rats fed ethoxyquin: role of induction of glutathione S-transferases. Cancer Res 1986, 46(8):3924-3931.
10. Sato Y, Mukai K, Watanabe S, Goto M, Shimosato Y: The AMEX method. A simplified technique of tissue processing and paraffin embedding with improved preservation of antigens for immunostaining. J Pathol 1986, 152(3):431-435.
11. Maxuotenko YY, Curphey TJ, Kensler TW, Roebuck BD: Protection against aflatoxin B1-induced hepatic toxicity as short-term screen of cancer chemopreventive dithiolethiones. Fundam Appl Toxicol 1996, 32(2):250-259.
12. Pugh TD, King JH, Koen H, Nychka D, Chover J, Wahba G, He YH, Goldfarb S: Reliable stereological method for estimating the number of microscopic hepatocellular foci from their intersections. Cancer Res 1983, 43(3):1261-1268.
13. Dashwood RH, Li Q, Dashwood R: Evidence for ras gene mutation in 2-amino-3-methylimidazo[4,5-f]quinoline-induced colonic aberrant crypts in the rat. Mol Carcinog 1995, 12(4):157-192.
14. Dashwood RH, Xu M, Orner GA, Horio DT: Colonic cell proliferation, apoptosis and aberrant crypt foci development in rats given 2-amino-3-methylimidazo[4,5-f]quinoline and treated post initiation with chlorophyllin. Eur J Cancer Prev 2001, 10(2):139-145.
15. Newberne PM, Suphakarn V: Preventive role of vitamin A in colon carcinogenesis in rats. Cancer 1977, 40(5 Supp):2553-2556.
16. Suphakarn VS, Newberne PM, Goldman M: Vitamin A and aflatoxin: effect on liver and colon cancer. Nutr Cancer 1983, 5(1):41-50.
17. Ward JM, Sontag JM, Weisburger JK, Brown CA: Effect of lifetime exposure to aflatoxin b1 in rats. J Natl Cancer Inst 1975, 55(1):107-113.
18. Deger LE: Letter: Aflatoxin--human colon carcinogenesis? Ann Intern Med 1976, 85(2):204-205.
19. Harrison JC, Farvaj M, Garner DC: Does aflatoxin exposure in the United Kingdom constitute a cancer risk? Environ Health Perspect 1993, 99:99-105.
20. Roebuck BD, Liu YL, Rogers AE, Groopman JD, Kensler TW: Protection against aflatoxin B1-induced hepatic tumors in F344 rats by 5-(2-pyrazyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry. Cancer Res 1991, 51(20):5501-5506.
21. Corpet DE, Tache S: Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer 2002, 43(1):1-21.
22. Caderini G, Femia AP, Giannini A, Favuzza A, Luceri C, Salvadori M, Dolara P: Identification of mucin-depleted foci in the unsectioned colon of azoxymethane-treated rats: correlation with carcinogenesis. Cancer Res 2003, 63(10):2388-2392.
23. Yoshimi N, Iorioka T, Kimjo T, Inamine M, Kaneshiro T, Shimizu T, Suzui M, Yamada Y, Mori H: Histological and immunohistochemical observations of mucin-depleted foci (MDF) stained with Alcian blue, in rat colon carcinogenesis induced by 1,2-dimethylhydrazine dihydrochloride. Cancer Sci 2004, 95(10):792-797.
24. Yamada Y, Yoshimi N, Hirose Y, Kawabata K, Matsunaga K, Shimizu M, Hara A, Mori H: Frequent beta-catenin gene mutations and accumulations of the protein in the putative preneoplastic lesions lacking macroscopic aberrant crypt foci appearance, in rat colon carcinogenesis. Cancer Res 2000, 60(13):3323-3327.
25. Yamada Y, Yoshimi N, Hirose Y, Matsunaga K, Katayama M, Sakata K, Shimizu M, Kuno T, Mori H: Sequential analysis of morphological and biological properties of beta- catenin-accumulated crypts, provable premalignant lesions independent of aberrant crypt foci in rat colon carcinogenesis. Cancer Res 2001, 61(5):1874-1878.
26. Paulsen JE, Namork E, Steffensen IL, Eide TJ, Alexander J: Identification and quantification of aberrant crypt foci in the colon of Min mice—a murine model of familial adenomatous polyposis. Scand J Gastroenterol 2000, 35(5):534-539.
27. Bird RP: Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 1987, 37(2):147-151.

28. Nascimbeni R, Villanacci V, Mariani PP, Di Betta E, Ghirardi M, Donato F, Salesi B: Aberrant crypt foci in the human colon: frequency and histologic patterns in patients with colorectal cancer or diverticular disease. Am J Surg Pathol 1999, 23(10):1256-1263.

29. Boustourene H, Chaubert P, Seelen tag W, Bosman FT, Saraga E: Aberrant crypt foci in patients with neoplastic and nonneoplastic colonic disease. Hum Pathol 1999, 30(1):66-71.

30. Rudolph RE, Dominitz JA, Lampe JW, Levy L, Qu P, Li SS, Lampe PD, Bronner MP, Potter JD: Risk factors for colorectal cancer in relation to number and size of aberrant crypt foci in humans. Cancer Epidemiol Biomarkers Prev 2005, 14(3):605-608.